This is an important and exciting international project. Hypoglycaemia is one of the most burdensome aspects of living with diabetes and deserves to be at the forefront of patient-centered research. The project is unique in addressing the problem of hypoglycaemia from a 360 degrees perspective. I am confident that this consortium of industry, fundamental researchers, clinicians and behavioural scientists, will make a significant contribution to improving the lives of many people with diabetes dealing with the burden of hypoglycaemia.Frank SnoekVU university medical center (VUmc)
In my opinion, the most exciting aspect of this unique project is its aim to clarify in more detail the role of the brain in hypoglycaemia counterregulation. In rodent models of type 1 diabetes and IAH, studies will focus on dishabituation (restoration of counterregulation) and on genetics in hypothalamic neurons involved in the glucagon response to hypoglycaemia. Also, the planned studies on cardiac consequences of recurrent hypoglycaemia in high-risk type 2diabetes are interesting and warranted.Marit BjörgaasNorwegian University of Science and Technology (NTNU)
I am extremely excited to be an advisor to such an interesting project as Hypo-RESOLVE. Being a coordinator of another IMI2 project, INNODIA, on biomarker discovery and clinical trial networking in type 1 diabetes, I will transmit any of our pioneering experience in this exciting concept of academic-private partnerships that IMI represents. Moreover, as a clinician, being part of a project studying one of the most important hurdles to good glycemic control and contributors to impaired quality of life in our patients with diabetes and their families, is of great value.Chantal MathieuINNODIA
This project provides a unique opportunity to better understand the underlying mechanisms and clinical determinants of hypoglycaemia in order to minimise its health, psychological and economic consequences for people with diabetes. It brings together leading clinical academic, basic science, psychosocial and health economic researchers supported by unprecedented industry cooperation, international diabetes organisations and an experienced project management team to ensure its success. I wish the investigators every success and look forward to the results, which will contribute to reducing the burden of hypoglycaemia for people with diabetes.Helen MurphyUniversity of East Anglia
Within its integrated approach, Hypo-RESOLVE brings together leading stakeholders from multidisciplinary research areas, industry partners, and patient organisations. External Advisory Groups will actively support Hypo-RESOLVE to obtain a clearer picture of the true impact of hypoglycaemia and its consequences: the Patient Advisory Committee and the Strategic Advisory Board. Additionally, an Ethics Board will be established to safeguard compliance with all ethical matters applicable to the research planned within the project. The expert groups will complement the expertise of the consortium and provide independent advice and recommendations to significantly bring forward research on hypoglycaemia.
The Patient Advisory Committee has been instrumental to Hypo-Resolve from the beginning of the project. The role of the PAC will be to give voice to the insights, desire and experiences of the patients to help ensure that Hypo-RESOLVE’s direction, goals and strategy are closely aligned with the goals of people living with, and affected by diabetes. This international committee, consisting of 7 people with type 1 or type 2 diabetes, representatives from the patient organizations IDF and JDRF and representatives from NovoNordisk, will help ensure that Hypo-RESOLVE operates with a patient-centric approach and delivers specific outcomes with the potential to improve the lives of people with diabetes.
The Patient Advisory Committee will be working within and across Work Packages serving as an advisory resource to Hypo-RESOLVE by for example:
The Hypo-RESOLVE consortium is delighted to have its expertise complemented by the Hypo-RESOLVE Strategic Advisory Board. Members of the Strategic Advisory Board comprise renowned scientists in the fields of Diabetes, Diabetes Technology, Hypoglycaemia and Medical Psychology, who provide scientific input for strategic decisions and give targeted feedback on the scientific progress of the project and therefore maximize benefits of the project.Members
The Hypo-RESOLVE Ethics Board was established at the beginning of the project and is composed of renowned independent experts with relevant and detailed knowledge of ethical policies. The experts represent the various aspects involved in Hypo-RESOLVE, including clinical studies, data protection, biobanks and database specialties.
The Ethics Board complements the Hypo-RESOLVE consortium by